Veracyte, Inc. VCYT
25.60 USD -0.33 (-1.25%)
Nov 10, 2026, 10:00 AM EST
24.58 Day range 25.68
21.91 52-week range 60.91
- YTD
- -39.20%
- 1 year
- -39.56%
- Market cap
- 2.07B
- Revenue (ttm)
- 581.78M
- Profit margin
- 21.80%
- EPS (ttm)
- 1.54
- Shares out
- 80.70M
- P/E ratio
- 16.62
- Forward P/E
- 14.39
- YTD return
- -39.20%
- 1-year return
- -39.56%
- Volume
- 174.51K
- Avg volume
- 1.67M
- Open
- 25.52
- Previous close
- 25.92
- Day's range
- 24.58 – 25.68
- 52-week range
- 21.91 – 60.91
- Beta
- 1.96
- Analysts
- Buy
- Price target
- 52.10 (+103.6%)
- Earnings date
- Feb 24, 2027
5D -23.96 (-48.04%)
Key statistics
- Enterprise value
- 1.62B
- PEG ratio
- 0.00
- Price / sales
- 3.60
- Price / book
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 15.10%
- Free cash flow
- 110.92M
- Total cash
- 370.53M
- Total debt
- 40.74M
- Return on equity
- 9.43%
- Short % of float
- 14.38%
- 50-day average
- 44.07
- 200-day average
- 42.76
Analyst view
Consensus: buy
Buy
Price target (mean) 52.10 +103.6% upside
Now 25.60
- Target (low)
- 35.00
- Target (mean)
- 52.10
- Target (high)
- 70.00
Ratings (0m) 12 9 buy · 3 hold · 0 sell
- Strong buy2
- Buy7
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.39898.
Financials — quick view
VCYT Revenue — quarterly 151.75M
VCYT Net income — quarterly 31.50M
VCYT EPS — quarterly 0.39
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.47 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.41 | 0.51 | +0.10 | +24.39% |
| Jul 30, 2026 | Jun 30, 2026 | 0.4103 | 0.54 | +0.13 | +31.61% |
| May 5, 2026 | Mar 31, 2026 | 0.34 | 0.52 | +0.18 | +52.94% |
| Feb 25, 2026 | Dec 31, 2025 | 0.4083 | 0.53 | +0.12 | +29.81% |
| Nov 4, 2025 | Sep 30, 2025 | 0.32 | 0.51 | +0.19 | +59.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Leerink Partners | down | Outperform | Market Perform |
| Nov 5, 2026 | Needham | main | Buy | Buy |
| Sep 15, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Sep 9, 2026 | UBS | main | Buy | Buy |
| Aug 4, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 4, 2026 | Stephens & Co. | main | Overweight | Overweight |
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- veracyte.com
News
Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30 
Freedom Capital Markets Maintains Buy on Veracyte, Lowers Price Target to $40 
UBS Maintains Buy on Veracyte, Lowers Price Target to $35 
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings 
Why Is Veracyte Stock Sinking Thursday? 
Dow Surges 250 Points; US Weekly Jobless Claims Fall 
Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session 
Leerink Partners Downgrades Veracyte to Market Perform, Lowers Price Target to $35
Your note
Sign in to keep a note on VCYT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARR ELIAV | Director | Stock Award(Grant) | Jun 10, 2026 | 56,461 |
| BHANJI MUNA | Director | Sale | Oct 18, 2026 | 40,854 |
| CHAMBERS REBECCA | Chief Financial Officer | Sale | Sep 3, 2026 | 166,025 |
| EPSTEIN ROBERT S | Director | Stock Award(Grant) | Jun 10, 2026 | 57,718 |
| FEBBO PHILLIP G | Officer | Sale | Sep 3, 2026 | 133,048 |
| HAAS KEVIN RICHARD | Officer | Stock Award(Grant) | Apr 9, 2026 | 44,221 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.78% | 13,486,437 | 349.57M | Jun 29, 2026 |
| FMR, LLC | 9.58% | 7,702,746 | 199.66M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 6.89% | 5,538,404 | 143.56M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.87% | 4,716,191 | 122.24M | Jun 29, 2026 |
| State Street Corporation | 5.84% | 4,698,128 | 121.78M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 3,593,922 | 93.15M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 4,787,107 | 124.08M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 2,532,110 | 65.63M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.90% | 2,332,081 | 60.45M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.60% | 2,092,968 | 54.25M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 1,830,642 | 47.45M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.07% | 1,666,407 | 43.19M | Sep 29, 2026 |